Prevention of human smooth muscle cell proliferation without induction of apoptosis by the topoisomerase I inhibitor topotecan (Q31803727)

3 July 2017

title

Prevention of human smooth muscle cell proliferation without induction of apoptosis by the topoisomerase I inhibitor topotecan (English)

1 reference

3 July 2017

Brehm BR

1

1 reference

3 July 2017

Bock C

2

1 reference

3 July 2017

Wesselborg S

3

1 reference

3 July 2017

Pfeiffer S

4

1 reference

3 July 2017

Schüler S

5

1 reference

3 July 2017

Schulze-Osthoff K

6

1 reference

3 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

3 July 2017

published in

Biochemical Pharmacology

1 reference

3 July 2017

volume

61

1 reference

3 July 2017

issue

1

1 reference

3 July 2017

page(s)

119-127

1 reference

Clinical trials of restenosis after coronary angioplasty

3 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Novel approach to the analysis of restenosis after the use of three new coronary devices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Smooth muscle cell phenotypes in atherosclerotic lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Arterial smooth muscle cells express platelet-derived growth factor (PDGF) A chain mRNA, secrete a PDGF-like mitogen, and bind exogenous PDGF in a phenotype- and growth state-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Molecular mechanisms in intimal hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

DNA topoisomerase poisons as antitumor drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Clinical applications of the camptothecins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Topoisomerase I inhibitors and other new cytotoxic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Biochemical and biophysical analyses of recombinant forms of human topoisomerase I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Induction of cell-rich and lipid-rich plaques in a transfilter coculture system with human vascular cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Clinical pharmacokinetics of topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Induction of Apoptosis by Camptothecin and Topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Antiangiogenic potential of camptothecin and topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Modulation of DNA Topoisomerase I Activity byp53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Topographical association between the cyclin-dependent kinases inhibitor P21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Expression of p53 protein and p53 gene transcripts in rabbit carotid arteries after balloon denudation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Topoisomerase I interacts with transcribed regions in Drosophila cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

DNA topoisomerase I and II activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C3H 10T1/2) cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900514-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-2952(00)00514-1

1 reference

3 July 2017

1 reference